Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

NCT05720260 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Premenopausal Breast Cancer
Metastatic Breast Cancer
ER Positive Breast Cancer

Interventions

DRUG: Goserelin
DRUG: Fulvestrant
DRUG: Capivasertib
DRUG: Durvalumab

Sponsor

National Taiwan University Hospital